<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="pmc">jkms</journal-id><journal-title>Journal of Korean Medical Science</journal-title><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8750055</article-id><article-id pub-id-type="pmc">3054155</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Y. R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yoo</surname><given-names>J. H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hur</surname><given-names>J. K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>J. H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shin</surname><given-names>W. S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>M. W.</given-names></name></contrib></contrib-group><aff>Department of Internal Medicine and Pediatrics, Catholic University Medical College, Seoul, Korea.</aff><pub-date pub-type="ppub"><month>10</month><year>1995</year></pub-date><volume>10</volume><issue>5</issue><fpage>314</fpage><lpage>317</lpage><abstract><p>The immunogenicity of a single dose of Salmonella typhi(S.typhi) Vi capsular polysaccharide(CPS) vaccine was evaluated before, and at 1, 3, 12, and 36 months after vaccination. Eighty-five adults(20-28 years of age) and sixty-four children(8-16 years of age) received a single dose of 25 micrograms Vi CPS vaccine intramuscularly, and antibody titers to Vi CPS were measured by passive hemagglutination. Of 149 vaccinees, 138(92.6%) showed seroconversion at 1 month after vaccination, and then 138 out of 141(97.9%) did at 3 months. Of 137 vaccinees, 116(84.7%) maintained a persistent rise in Vi antibody titer 12 months after vaccination, and 55 out of 100(55.0%) had a 4-fold or greater rise at 36 months. No significant adverse reactions were observed. Booster injection may be needed 3-5 years after vaccination.</p></abstract></article-meta></front></article>

